High-dose bosentan in the prevention and treatment of subarachnoid hemorrhage-induced cerebral vasospasm: An open-label feasibility study

Neurocritical Care

Volumn 7, Issue 3, 2007, Pages 194-202

  Nogueira, Raul G ^a   Bodock, Michael J ^a   Koroshetz, Walter J ^a   Topcuoglu, Mehmet A ^a   Carter, Bob S ^a   Ogilvy, Christopher S ^a   Pryor, Johnny C ^a   Buonanno, Ferdinando S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antagonist; Bosentan; Endothelin; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

BOSENTAN; NIMODIPINE;

ADULT; ANEMIA; ARTICLE; BRAIN VASOSPASM; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FLUSHING; HEADACHE; HUMAN; LIVER TOXICITY; MALE; NEUROIMAGING; PRIORITY JOURNAL; SIDE EFFECT; SUBARACHNOID HEMORRHAGE;

ADULT; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; VASOSPASM, INTRACRANIAL;

EID: 36949003702     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-007-0070-4     Document Type: Article

References (38)

1. Warlow CD, Dennis MS, Van Gijn J, Hankey GJ, Sandercock PAG, Bamford JM, Wardlaw JM. Specific treatment of aneurysmal subarachnoid haemorrhage. In: Stroke - A practical guide to management, 2nd ed. Blackwell Science Inc; February 2001.
2. Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology 1998;50:1413-8.
3. Kistler JP, Crowell RM, Davis KR, et al. The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT scan: a prospective study. Neurology 1983;33:424-36.
4. Adams HP Jr., Kassell NF, Torner JC, Haley EC Jr. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology 1987;37:1586-91.
5. Treggiari-Venzi MM, Suter PM, Romand JA. Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care. Neurosurgery 2001;48:249-61; discussion 261-2.
6. Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery 1998;43:863-75; discussion 875-6.
7. Chow M, Dumont AS, Kassell NF. Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 2002;51:1333-41; discussion 1342.
8. Zuccarello M, Boccaletti R, Romano A, Rapoport RM. Endothelin B receptor antagonists attenuate subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 1998;29:1924-9.
9. Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 1989;2:1402.
10. Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 2000;92:390-400.
11. Juvela S. Plasma endothelin and big endothelin concentrations and serum endothelin-converting enzyme activity following aneurysmal subarachnoid hemorrhage. J Neurosurg 2002;97:1287-93.
12. Ehrenreich H, Lange M, Near KA, et al. Long term monitoring of immunoreactive endothelin-1 and endothelin-3 in ventricular cerebrospinal fluid, plasma, and 24-h urine of patients with subarachnoid hemorrhage. Res Exp Med (Berl) 1992;192:257-68.
13. Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 1995;82:55-62.
14. Suzuki K, Meguro K, Sakurai T, Saitoh Y, Takeuchi S, Nose T. Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. Surg Neurol 2000;53:131-5.
15. Badjatia N, Topcuoglu MA, Pryor JC, et al. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol 2004;25:819-26.
16. Lindegaard KF, Nornes H, Bakke SJ, Sorteberg W, Nakstad P. Cerebral vasospasm after subarachnoid haemorrhage investigated by means of transcranial Doppler ultrasound. Acta Neurochir Suppl (Wien) 1988;42:81-4.
17. Soustiel JF, Shik V, Shreiber R, Tavor Y, Goldsher D. Basilar vasospasm diagnosis: investigation of a modified "Lindegaard Index" based on imaging studies and blood velocity measurements of the basilar artery. Stroke 2002;33:72-7.
18. Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968;28:14-20.
19. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998;338:784-90.
20. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35.
21. Zuccarello M, Soattin GB, Lewis AI, Breu V, Hallak H, Rapoport RM. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 1996;84:503-7.
22. Zimmermann M, Seifert V, Loffler BM, Stolke D, Stenzel W. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist. Neurosurgery 1996;38:115-20.
23. Roux S, Loffler BM, Gray GA, Sprecher U, Clozel M, Clozel JP. The role of endothelin in experimental cerebral vasospasm. Neurosurgery 1995;37:78-85; discussion 85-6.
24. Shigeno T, Clozel M, Sakai S, Saito A, Goto K. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 1995;37:87-90; discussion 90-1.
25. Zimmermann M. Endothelin in cerebral vasospasm. Clinical and experimental results. J Neurosurg Sci 1997;41:139-51.
26. Hino A, Weir BK, Macdonald RL, Thisted RA, Kim CJ, Johns LM. Prospective, randomized, double-blind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. J Neurosurg 1995;83:503-9.
27. Wallnofer A, Grosset D, Ohman J, Zubkov Y, Mendelow A, Jones R, Teasdale G. Effects of the endothelin antagonist bosentan in patients with elevated Doppler velocities after aneurysmal SAH. In: Proceedings of the 6th International Conference on Cerebral Vasospasm; May 1997: Session 16:99-100.
28. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 2000;93:992-7.
29. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005;103:9-17.
30. Macdonald RL, Kassell N, Mayer S, Schmiedek P, Weidauer S, Pasqualin A. Randomized trial of clazosentan for prevention of vasospasm after aneurysmal subarachnoid hemorrhage. In: International Stroke Conference; 2007. San Francisco, CA.
31. Qureshi AI, Sung GY, Razumovsky AY, Lane K, Straw RN, Ulatowski JA. Early identification of patients at risk for symptomatic vasospasm after aneurysmal subarachnoid hemorrhage. Crit Care Med 2000;28:984-90.
32. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-8.
33. Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997;283:1110-8.
34. Zuccarello M, Lewis AI, Rapoport RM. Endothelin ETA and ETB receptors in subarachnoid hemorrhage-induced cerebral vasospasm. Eur J Pharmacol 1994;259:R1-2.
35. Hansen-Schwartz J, Hoel NL, Zhou M, Xu CB, Svendgaard NA, Edvinsson L. Subarachnoid hemorrhage enhances endothelin receptor expression and function in rat cerebral arteries. Neurosurgery 2003;52:1188-94; 1194-5.
36. Hansen-Schwartz J, Szok D, Edvinsson L. Expression of ET(A) and ET(B) receptor mRNA in human cerebral arteries. Br J Neurosurg 2002;16:149-53.
37. Seo B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994;89:1203-8.
38. Mickley EJ, Gray GA, Webb DJ. Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol 1997;120:1376-82.